ESSA Pharma Inc. (EPIX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
EPIX currently has 44.4M outstanding shares. with limited dilution risk as only 7.37M additional shares (16.6%) are authorized for issuance. The company has minimally diluted shareholders by 0.25% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Oct 15, 2025 |
POS AM filing: This is a post-effective amendment to withdraw unsold securities from a previous registration statement due to the termination of offerings following a business combination agreement. |
44M | 7.4M |
| Aug 13, 2025 |
10-Q filing | 44.4M shares outstanding |
44M | 7.4M |
| May 08, 2025 |
10-Q filing | 44.4M shares outstanding |
44M | 7.4M |
| Feb 11, 2025 |
10-Q filing | 44.4M shares outstanding |
44M | 7.4M |
| Dec 17, 2024 |
10-K filing | 44.3M shares outstanding |
44M | 7.4M |
| Aug 05, 2024 |
10-Q filing | 44.4M shares outstanding |
44M | 7.4M |
| May 14, 2024 |
10-Q filing | 44.2M shares outstanding |
44M | 7.4M |
| Feb 13, 2024 |
10-Q filing | 44.1M shares outstanding |
44M | 7.4M |
| Dec 12, 2023 |
10-K filing | 44.1M shares outstanding |
44M | 7.4M |
| Oct 03, 2023 |
S-3/A filing: ESSA PHARMA INC. files an S-3/A indicating they may offer and sell common shares, preferred shares, debt securities, subscription receipts, warrants to purchase common shares and units or any combination thereof up to an aggregate initial offering price of up to US$200,000,000 under a shelf prospectus. |
44M | 7.4M |
| Sep 19, 2023 |
S-3 filing: ESSA Pharma Inc. is filing an S-3 to offer common shares, preferred shares, debt securities, subscription receipts, warrants to purchase common shares and units or any combination thereof up to an aggregate initial offering price of up to US$200,000,000. |
44M | 7.4M |
| Aug 08, 2023 |
10-Q filing | 44.1M shares outstanding |
44M | 7.4M |
| May 09, 2023 |
10-Q filing | 44.1M shares outstanding |
44M | 7.4M |
| Feb 07, 2023 |
10-Q filing | 44.1M shares outstanding |
44M | 7.4M |
| Dec 13, 2022 |
10-K filing | 44.0M shares outstanding |
44M | 7.4M |
| Aug 04, 2022 |
10-Q filing | 44.1M shares outstanding |
44M | 7.4M |
| May 10, 2022 |
10-Q filing | 44.0M shares outstanding |
44M | 7.4M |
| Feb 03, 2022 |
10-Q filing | 44.0M shares outstanding |
44M | 7.4M |
| Nov 18, 2021 |
10-K filing | 44.0M shares outstanding |
44M | 7.4M |
| Aug 16, 2021 |
10-Q filing | 32.1M shares outstanding |
32M | 7.4M |
| May 06, 2021 |
10-Q filing | 32.1M shares outstanding |
32M | 7.4M |
| Feb 22, 2021 |
8-K filing: ESSA Pharma Inc. closed an offering of 4,830,918 common shares, resulting in approximately $130 million of gross proceeds, to be used for clinical activities, manufacturing, research and development, working capital, and general corporate purposes. ($130.0M proceeds) |
32M | 7.4M |
| Feb 11, 2021 |
10-Q filing | 32.1M shares outstanding |
32M | 38M |
| Dec 23, 2020 |
S-3/A filing: ESSA Pharma Inc. is offering 7,370,000 common shares for resale by selling shareholders. The company will not receive any proceeds from the sale of these shares. |
21M | 38M |
| Dec 23, 2020 |
S-3/A filing: ESSA Pharma Inc. may offer and issue common shares, preferred shares, debt securities, subscription receipts, warrants to purchase common shares and units or any combination thereof up to an aggregate initial offering price of up to US$200,000,000 in one or more transactions under this shelf prospectus. |
21M | 38M |
| Dec 15, 2020 |
10-K filing | 20.8M shares outstanding |
21M | 38M |
| Nov 25, 2020 |
S-3 filing: ESSA Pharma Inc. is offering 7,370,000 common shares for resale by selling shareholders. |
N/A | 38M |
| Nov 25, 2020 |
S-3 filing: ESSA PHARMA INC. is filing an S-3 to offer common shares, preferred shares, debt securities, subscription receipts, warrants to purchase common shares and units or any combination thereof up to an aggregate initial offering price of up to US$200,000,000. |
N/A | 38M |